All In MedTech

FDA Clearance Tracker · P000058-S096

Infuse Bone Graft

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplementBreakthrough

Decided

Feb 13, 2026

Approved

Time to decision

178 days

Received Aug 19, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P000058-S096
Device name
Infuse Bone Graft
Applicant location
Memphis, TN
Received
Aug 19, 2025
Decided
Feb 13, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P000058

Device type

Device class
Class III

Every decision under product code NEK

FDA's approval statement

As written in FDA's record.

Infuse™ Bone Graft with an FDA cleared intervertebral body fusion device and metallic screw-and-rod system is indicated for use in a transforaminal lumbar interbody fusion (TLIF) surgical approach at one or two adjacent levels from L2-S1 in the treatment of symptomatic degenerative disc disease (DDD) confirmed by patient history and radiographic studies and having at least six months of nonoperative treatment attempted prior to treatment with Infuse™ Bone Graft.

Source documents

Other decisions for Medtronic Sofamor Danek USA, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.